Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Updated KEYNOTE-564 Data Continue to Underscore Benefit of Adjuvant Pembrolizumab in RCC

March 22nd 2022

Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.

Dr. Spiess on the Rationale for Investigating the MTAP Pathway in Genitourinary Cancers

March 21st 2022

Philippe E. Spiess, MD, MS, FACS, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.

Advanced Renal Cell Carcinoma and Brain Metastases

March 21st 2022

Experts discuss how to treat advanced renal cell carcinoma with brain metastases and when to refer patients to an academic center.

Nivolumab + Ipilimumab Therapy as Frontline Therapy for Advanced Renal Cell Carcinoma

March 21st 2022

Treating a patient with advanced renal cell carcinoma with ipilimumab-nivolumab based on data from the CheckMate 214 trial.

I/O–I/O Therapy in Intermediate/Poor Risk RCC: Toxicity and Duration of Response

March 18th 2022

Focusing on immunotherapy in the setting of intermediate- and poor-risk renal cell carcinoma, panelists review toxicity management and duration of response.

Patient Profile 1: Intermediate/Poor Risk RCC Treated With Ipilimumab-Nivolumab

March 18th 2022

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance.

First-Line Therapy of Advanced RCC With Lenvatinib + Pembrolizumab: CLEAR Study

March 16th 2022

Mehmet A. Bilen, MD, discusses the CLEAR trial that looked at lenvatinib with pembrolizumab as first-line therapy for RCC.

Advanced RCC: Brief Overview

March 16th 2022

Tian Zhang, MD, provides an overview of renal cell carcinoma (RCC).

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

March 16th 2022

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Dr. Iacovelli on Next Steps of the ARIES Trial in Urothelial Cancer

March 15th 2022

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Allarity Therapeutics Requests Type C Meeting With FDA to Discuss Dovitinib in Third-Line RCC

March 15th 2022

Allarity Therapeutics, Inc. has filed a formal request with the FDA to hold a Type C meeting where they can discuss possible clinical paths to support the approval of dovitinib in renal cell carcinoma, as well as its DRP-Dovitinib companion diagnostic.

Patient Profile Presentation: A 41-Year-Old Male with Advanced Renal Cell Carcinoma

March 14th 2022

Sumeet Bhatia, MD, presents the patient profile of a 47-year-old male patient with advanced renal cell carcinoma.

Impact of Adjuvant Pembrolizumab Approval on RCC Treatment Landscape

March 14th 2022

Two key opinion leaders review data from a phase 3 clinical trial assessing the use of lenvatinib plus pembrolizumab for the treatment of advanced renal cell carcinoma.

Analysis of Genomic Alterations in Metastases Could Help Inform Treatment in RCC

March 10th 2022

Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.

Adverse Events with IO-TKI Combination Treatment Regimens

March 7th 2022

Two oncologists describe common adverse events seen with I/O–TKI combination treatment regimens for advanced renal cell carcinoma and when they choose to stop the therapy.

Lenvatinib + Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma

March 7th 2022

Dr Eric Jonasch discusses why he chose to treat his patient’s advanced renal cell carcinoma with lenvatinib-pembrolizumab and how he modifies the dosage throughout treatment.

Dr. Choueiri on the Design of KEYNOTE-564 in RCC

March 2nd 2022

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Network Meta-Analysis Evaluates New Decision Algorithm for Fractional Polynomial Selection in First-Line RCC Treatment

February 28th 2022

A clinical algorithm-based approach that was developed to improve fractional polynomial model selection utilized additional criteria based on face validity, predictive accuracy, and expert opinion, which improved the plausibility of survival outcomes in patients with renal cell carcinoma.

Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma

February 28th 2022

Sumeet Bhatia, MD, explains the factors he considers in choosing a treatment for advanced renal cell carcinoma and the role biomarkers have in the process.

Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma

February 28th 2022

Eric Jonasch, MD, presents a real world advanced renal cell carcinoma patient profile and reviews the available first-line IO-TKI combination treatment regimens.